Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by P. Shankaraiah
Total Records ( 3 ) for P. Shankaraiah
  P. Shankaraiah , Y. Narsimha Reddy , A. Venkatesham , N. Venkata Rajaiah and D.R. Krishna
  Glucokinase (GK) is a type IV isoenzyme that belongs to the family of hexokinases. GK plays a role in the glucose metabolism of the liver and a glucose sensor in pancreatic β-cells involved in glucose-dependent insulin release Therefore we estimated the glucokinase levels in Indian type 2 diabetic populations. Selection of the study group was as follows: (1) Twenty nondiabetic subjects (control group), (2) thirty newly detected diabetic patients (without treatment), (3) forty three diabetic patients on combination treatment (4) thirty diabetic patients on pioglitazone alone treated. In all the subjects Anti diabetic activity criterion was taken for the diagnosis. In the same subjects fasting and post-prandial GK enzyme levels were estimated. Fasting and post-prandial Glucokinase levels in different groups were statistically significant, except between the non diabetic vs. anti diabetic drug treated group. It showed significant p-value regarding fasting and post-prandial glucokinase levels. Glucokinase levels in oral antidiabetic (combination) drugs (4.3±1.4 and 5.8±1.1 U L-1) and pioglitazone alone treated groups showed significantly higher (3.84±0.9 and 5.1±0.7 U L-1) than newly diagnosed type-2 diabetic patients (3.5±1.1 and 1.7±0.7 U L-1) in fasting and post-prandial condition. Fasting and post-prandial glucokinase levels were low in newly detected, raised in drug-treated diabetic subjects and varied significantly increased in treated diabetic group. This change may be attributed to chronicity of diabetes due to effect of pioglitazone on post-prandial Glucokinase levels.
  P. Shankaraiah and Y.N. Reddy
  α-amylases are enzymes which hydrolyze starch molecules to give diverse products including dextrins and progressively smaller polymers composed of glucose units which causes hyperglycemia and development of type 2 diabetes mellitus. Therefore, we estimated the α-amylase activity, HbA1C and blood glucose in Indian type 2 diabetic patients. Study group’s follows: 20 Healthy subjects, 30 newly detected patients and 43 type 2 diabetics on treatment with metformin and pioglitazone combination and 30 pioglitazone alone treated. In all subjects blood sugar was estimated and anti diabetic activity criterion was taken for the diagnosis. In the same subjects fasting and post-prandial α-amylase activity was estimated, HbA1c levels were compared with α-amylase activity in healthy and treated subjects. The α-amylase activity in type 2 diabetic patients was significantly different from control subjects and significant relation between α-amylase activity and HbA1c was observed in diabetic subjects (p<0.01), in type 2 diabetic patients with HbA1c >12% showed significantly (p<0.01) higher α-amylase activity than newly diagnosed and healthy, for three months treatment in type 2 diabetic patients showed a significant controlled the blood glucose, elevated alpha amylase levels. Post-prandial α-amylase activity was markedly raised in type 2 diabetes, this could contribute to the increased in circulating blood glucose. Fasting and post-prandial α-amylase activity and lipid profiles were significantly controlled in pioglitazone alone and pioglitazone with metformin combination treated groups. This change may effect of metformin and pioglitazone on post-prandial α-amylase activity.
  B. Ravichandra , P. Saketh Ram , Ch. Saritha and P. Shankaraiah
  The study aim is to investigate the Anti diabetic an anti dyslipidemic activity of Cleome gynandra plant extract in alloxan-induced diabetic rats. The effects of orally administered ethanolic extract of Cleome gynandra on serum glucose and lipid profiles activity were examined in diabetic control and Cleome gynandra treated diabetic rats. While the activity of the blood glucose and lipid profiles, in the serum were assessed. The drugs were administered over a period of 7 days treatment. The Cleome gynandra was significantly (p<0.05) reduced the serum glucose, elevated dyslipidemia levels, SGOT and SGPT levels, in alloxan induced group, Metformin treated group, EECG-I group, EECG-II groups but increased the serum HDL status in all the ethanolic extract Cleome gynandra treated groups, compared with normal control and diabetic control. The present investigation suggested that ethanolic extract of Cleome gynandra was inhibits blood glucose levels and dyslipidemea in diabetes rats.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility